Market research
LGVN Longeveron LLC
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 27M
- P/E ratio
- Not available
- Analyst target
- 7.15
- Dividend yield
- Not available
- Beta
- -0.25
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US54303L2034
- Market cap
- 27M
- P/E ratio
- Not available
- Analyst target
- 7.15
- Dividend yield
- Not available
- Beta
- -0.25
About
About Longeveron LLC
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States. Its lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors which is in phase 3 clinical trial to treat hypoplastic left heart syndrome; completed phase 2a clinical trial to treat Alzheimer's disease, as well as in phase 2b clinical trial to treat aging frailty. The company was incorporated in 2014 and is headquartered in Miami, Florida.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the LGVN discussion.
5 years, 4 months ago
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Other sector with a price to sales ratio of 0.0.
Based on the above factors, Longeveron Inc. Class A Common Stock gets an overall score of 1/5.